SELLAS Life Sciences Group, Inc. Research and Development Asset Acquired Other than Through Business Combination, Written-off
SELLAS Life Sciences Group, Inc. (SLS) reported Research and Development Asset Acquired Other than Through Business Combination, Written-off of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-28.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff · last filed 2024-03-28
- SELLAS Life Sciences Group, Inc. research and development asset acquired other than through business combination, written-off for the quarter ending 2023-12-31 was $0.00.
- SELLAS Life Sciences Group, Inc. research and development asset acquired other than through business combination, written-off for the quarter ending 2023-09-30 was $0.00.
- SELLAS Life Sciences Group, Inc. research and development asset acquired other than through business combination, written-off for the quarter ending 2023-06-30 was $0.00.
- SELLAS Life Sciences Group, Inc. research and development asset acquired other than through business combination, written-off for the quarter ending 2023-03-31 was $0.00.
- SELLAS Life Sciences Group, Inc. research and development asset acquired other than through business combination, written-off for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- SELLAS Life Sciences Group, Inc. research and development asset acquired other than through business combination, written-off for fiscal 2022 was $10.00M.
| Period end | Research and Development Asset Acquired Other than Through Business Combination, Written-off 3 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 6 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 9 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $0.00 derived: sum of 2 quarters · filed 2024-03-28 | $0.00 derived: sum of 3 quarters · filed 2024-03-28 | $0.00 10-K · filed 2024-03-28 |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-09 | $0.00 derived: sum of 2 quarters · filed 2023-11-09 | $0.00 10-Q · filed 2023-11-09 | $0.00 derived: sum of 4 quarters · filed 2024-03-28 |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-10 | $0.00 10-Q · filed 2023-08-10 | $0.00 derived: sum of 3 quarters · filed 2024-03-28 | $0.00 derived: sum of 4 quarters · filed 2024-03-28 |
| 2023-03-31 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2024-03-28 | $0.00 derived: sum of 2 quarters · filed 2024-03-28 | $0.00 derived: sum of 3 quarters · filed 2024-03-28 | $0.00 derived: sum of 4 quarters · filed 2024-03-28 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $0.00 derived: sum of 2 quarters · filed 2024-03-28 | $0.00 derived: sum of 3 quarters · filed 2024-03-28 | $10.00M 10-K · filed 2024-03-28 |
| 2022-09-30 | $0.00 10-Q · filed 2023-11-09 | $0.00 derived: sum of 2 quarters · filed 2023-11-09 | $10.00M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $0.00 10-Q · filed 2023-08-10 | $10.00M 10-Q · filed 2023-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |